# An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication in Male Emergency Department (ED) Subjects

> **NCT04996056** · PHASE2 · WITHDRAWN · sponsor: **Tonix Pharmaceuticals, Inc.**

## Conditions studied

- Cocaine Intoxication

## Interventions

- **DRUG:** TNX-1300
- **OTHER:** Usual Care

## Key facts

- **NCT ID:** NCT04996056
- **Lead sponsor:** Tonix Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-09-03
- **Primary completion:** 2022-06-16
- **Final completion:** 2022-06-16
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Not able to recruit qualified participants
- **Last updated:** 2022-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04996056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04996056, "An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication in Male Emergency Department (ED) Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04996056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*